There is a dosing conversation in functional medicine that most training programs skip entirely. The distinction between nutritional support dosing and pharmacological-level nutraceutical dosing changes patient outcomes, risk profiles, and the clinical reasoning behind every supplement recommendation.
What the Distinction Means
Nutritional support dosing is what it sounds like: providing nutrients at levels intended to correct deficiencies, support physiological function, and maintain optimal nutrient status. A patient with suboptimal vitamin D levels takes 2,000-5,000 IU daily. A patient with low B12 takes a methylcobalamin supplement. The goal is to bring a depleted system back to adequate levels.
Pharmacological-level dosing uses nutrients or botanical compounds at concentrations intended to produce a therapeutic effect on a specific physiological pathway. High-dose curcumin to modulate NF-kB inflammatory signaling. High-dose resveratrol to influence SIRT1 activity. Glutathione precursors at levels designed to upregulate phase II detoxification capacity. The goal is not to correct a deficiency. The goal is to use the compound as a clinical intervention.
Both approaches have their place. The problem is when practitioners use one without recognizing they are actually doing the other.
Why the Distinction Matters Clinically
A practitioner recommending high-dose fish oil to modulate inflammatory pathways is making a pharmacological decision, not a nutritional one. That decision should carry the same clinical reasoning as any therapeutic intervention: what is the mechanism of action, what is the expected response, what are the contraindications, how will you monitor the effect, and what is the exit strategy if the desired response does not occur.
When these distinctions are not made explicit, several problems arise. Patients take therapeutic doses indefinitely because no one set a clinical endpoint. Practitioners stack multiple high-dose compounds without considering their cumulative effects on the same pathway. Interactions with pharmaceuticals are missed because the supplements are mentally categorized as “just nutritional support” when they are functioning as therapeutic agents.
The reverse problem is equally common. Practitioners recommend nutritional-support doses of compounds and expect pharmacological results. A patient takes a modest dose of turmeric and the practitioner wonders why the inflammatory markers did not shift. The dose was never in the therapeutic range for the intended mechanism.
How This Applies in Practice
The clinical question is always the same: what am I trying to achieve with this compound, and does the dose match the objective?
If the objective is to maintain adequate nutrient status, nutritional-support dosing is appropriate. The monitoring is straightforward: retest levels, adjust accordingly.
If the objective is to produce a measurable change in a physiological pathway, the dosing needs to reflect the research on therapeutic thresholds for that specific application. The monitoring should include markers that reflect the target pathway, not just the nutrient level. And the intervention should have a defined clinical timeline, because pharmacological-level dosing that continues indefinitely without reassessment is not evidence-based practice.
This also applies to patient communication. A patient who understands they are taking a compound at a therapeutic dose for a defined clinical purpose, with monitoring and a timeline, is a more compliant and more engaged patient than one who is simply told to “take this supplement.”
Where to Develop This Clinical Reasoning
The Kharrazian Institute curriculum addresses nutraceutical applications within each clinical topic area. Rather than teaching supplement protocols in isolation, each foundational course integrates nutritional and botanical interventions into the clinical sequence of thought for that condition. Practitioners learn not just what to recommend but how to dose it relative to the clinical objective, how to monitor the response, and when to adjust or discontinue.
Dr. Datis Kharrazian has consulted with the nutrition industry and formulated over 100 clinical products used by practitioners worldwide. That formulation expertise informs the curriculum’s approach to dosing strategy, compound selection, and the clinical reasoning behind each recommendation.
Explore the program overview or start a free 7-day trial to see how KI integrates nutraceutical strategy into clinical training.
